Targeting the oncogenic activity of TCF3-HLF in leukemia

Yun Huang; Jean-Pierre Bourquin

doi:10.1080/23723556.2019.1709391

Targeting the oncogenic activity of TCF3-HLF in leukemia

Mol Cell Oncol. 2020 Mar 18;7(3):1709391. doi: 10.1080/23723556.2019.1709391. eCollection 2020.

Authors

Yun Huang¹, Jean-Pierre Bourquin¹

Affiliation

¹ Division of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland.

Abstract

The oncogenic fusion transcription factor TCF3-HLF identifies an aggressive subtype of acute lymphoblastic leukemia. TCF3-HLF imposes a malignant program by activation of lineage-specific oncogenic enhancers. Among critical cofactors of the TCF3-HLF complex we identified EP300, which functional inhibition results in potent anti-leukemic activity by interference with the specific gene expression.

Keywords: Leukemia; TCF3-HLF; chimeric transcription factor; drug resistance; enhancer.

Grants and funding

This work was supported by the Swiss Cancer League [KFS-3526-08-2014; KFS-4237-08-2017]; the Swiss National Research Foundation SNF [310030-133108 and 323530-164223]; the foundation ‘Kinderkrebsforschung Schweiz’, the ‘Krebsliga Zurich’, the Novartis Foundation of Biomedical Research, the clinical research focus program ‘Human Hemato-Lymphatic Diseases’ of the University of Zurich, the Iten-Kohaut Stiftung, the Panacée Foundation, the Innovative Medicines Initiative project ULTRA-DD [FP07/2007-2013, grant no. 115766], the German Federal Office for Radiation Protection [grant St.Sch. 3611S70014]; and by the Max Planck Society.